Related Experiment Video
Updated: Jan 17, 2026

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
Published on: October 16, 2021
A Novel Management to Severe Hypoattenuation Leaflet Thickening Following Transcatheter Aortic Valve Replacement
Himax Patel1, John Lester2, Amr Essa1
1Department of Cardiology, Wellstar Medical College of Georgia Health Medical Center, Augusta, Georgia, USA.
•First reported tissue plasminogen activator use to treat hypoattenuated leaflet thickening (HALT) post-transcatheter aortic valve replacement unresponsive to standard therapy.•Low-dose thrombolysis over 48 hours restored valve function.•Complete HALT resolution confirmed on computed tomography angiography after thrombolysis.
•First reported tissue plasminogen activator use to treat hypoattenuated leaflet thickening (HALT) post-transcatheter aortic valve replacement unresponsive to standard therapy.•Low-dose thrombolysis over 48 hours restored valve function.•Complete HALT resolution confirmed on computed tomography angiography after thrombolysis.
Related Concept Videos
Aortic Regurgitation III: Medical Management
Mitral Stenosis III: Medical Management
Mitral Regurgitation III: Medical Management
Mitral Valve Prolapse III: Nursing Management
Aortic Regurgitation IV: Nursing Management
Mitral Valve Prolapse II: Assessment and Management

